david_roblin__picture_o

Ex-Pfizer R&D head Dr David Roblin joins Destiny Pharma

pharmafile | November 7, 2011 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Destiny Pharma, Pfizer, R&D 

Anti-microbial drug developers Destiny Pharma have appointed Dr David Roblin as its new medical director.

Dr Roblin was formerly head of research at Pfizer’s R&D operations in Sandwich, Kent, but left the company in March after Pfizer announced it would be closing the site, with the lost of around 2,000 jobs.

Having held senior roles at Pfizer and Bayer Dr Roblin brings 15 years of R&D expertise to Destiny Pharma as well as five years’ experience of medical practice. 

He said: “After leaving Pfizer I wanted to work with smaller companies where I believe there is a good chance to bring important new medicines to patients and value to investors.

“I was attracted to the science coming out of Destiny. It is creating a class of antibiotics unique in its rapid activity and its efficacy on resistant organisms that are causing many problems in medical practice.”

Founded in 1997 Destiny Pharma has developed a pipeline of drugs designed to avoid the microbial resistance problems associated with traditional antibiotics.

The Brighton-based firm is currently preparing for the later stages of developing and commercialising XF-73, its lead product for the prevention of post-surgical Staphylococcal infection, the world’s most common cause of hospital bacterial infection.

Related Content

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of …

AbbVie invests €150m in new R&D facility in Germany

AbbVie has announced that it is investing approximately €150m in its second largest research and …

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …

Latest content